{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06515418",
            "orgStudyIdInfo": {
                "id": "BGE-105-005"
            },
            "organization": {
                "fullName": "BioAge Labs, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared With Tirzepatide Alone in Participants With Obesity Aged 55 Years and Over",
            "officialTitle": "A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Proof-of-Concept Study to Investigate Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared With Tirzepatide Alone in Participants With Obesity Aged 55 Years and Over (STRIDES)",
            "acronym": "STRIDES",
            "therapeuticArea": [
                "Endocrinology"
            ],
            "study": "efficacy-and-safety-of-oral-azelaprag-plus-once-weekly-tirzepatide-compared-with-tirzepatide-alone-in-participants-with-obesity-aged-years-and-over"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-06-27",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-09",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-07-17",
            "studyFirstSubmitQcDate": "2024-07-17",
            "studyFirstPostDateStruct": {
                "date": "2024-07-23",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-17",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-23",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "BioAge Labs, Inc.",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "Eli Lilly and Company",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study aims to find out how well a combination of oral azelaprag taken once a day (QD) or twice a day (BID), along with a weekly injection of tirzepatide, works for weight management in adults 55 years and older. The researchers are also looking at safety.\n\nEstimated Study Length:\n\n* with the optional prescreening, the study duration may be up to 48 weeks.\n* the treatment duration will be 24 weeks followed by 12 weeks follow-up.\n* the visit frequency will be every 2 weeks for the first 8 weeks of the treatment period and every 4 weeks thereafter.",
            "detailedDescription": "Clinical trial BGE-105-005 will determine if the addition of oral azelaprag to tirzepatide treatment will amplify overall weight loss in participants with obesity aged 55 years and older. BGE-105-005 is a randomized, double-blind, placebo-controlled, parallel-arm, multi-center study in approximately 220 adults \u226555 years old with body mass index (BMI) between 30 and 40 kg/m2 inclusive, at the time of screening. Participants will be randomly assigned to 1 of the 4 study arms (A-tirzepatide monotherapy, B-azelaprag 300 mg QD plus tirzepatide, C-azelaprag 300 mg BID plus tirzepatide, D-azelaprag 300 mg BID monotherapy). The primary endpoint will be the effect on body weight reduction as measured by mean percent change in body weight at 24 weeks in participants that received azelaprag plus tirzepatide versus tirzepatide alone. The study is intended to gather safety and efficacy data in the defined participant population."
        },
        "conditionsModule": {
            "conditions": [
                "Obesity"
            ],
            "keywords": [
                "Azelaprag",
                "BGE-105",
                "BioAge",
                "Tirzepatide",
                "Weight Management",
                "GLP-1/GIP Receptor Agonist",
                "STRIDES"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "TRIPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 220,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "A: Tirzepatide Monotherapy",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "* Azelaprag placebo every morning\n* Azelaprag placebo every evening\n* Tirzepatide 5mg once weekly",
                    "interventionNames": [
                        "Drug: Oral Placebo for Azelaprag (BGE-105)",
                        "Drug: Tirzepatide"
                    ]
                },
                {
                    "label": "B: Azelaprag once daily plus Tirzepatide",
                    "type": "EXPERIMENTAL",
                    "description": "* Azelaprag 300mg every morning\n* Azelaprag placebo every evening\n* Tirzepatide 5mg once weekly",
                    "interventionNames": [
                        "Drug: Oral Azelaprag (BGE-105)",
                        "Drug: Oral Placebo for Azelaprag (BGE-105)",
                        "Drug: Tirzepatide"
                    ]
                },
                {
                    "label": "C: Azelaprag twice daily plus Tirzepatide",
                    "type": "EXPERIMENTAL",
                    "description": "* Azelaprag 300mg every morning\n* Azelaprag 300mg every evening\n* Tirzepatide 5mg once weekly",
                    "interventionNames": [
                        "Drug: Oral Azelaprag (BGE-105)",
                        "Drug: Tirzepatide"
                    ]
                },
                {
                    "label": "D: Azelaprag Monotherapy",
                    "type": "EXPERIMENTAL",
                    "description": "* Azelaprag 300mg every morning\n* Azelaprag 300mg every evening\n* Tirzepatide placebo once weekly",
                    "interventionNames": [
                        "Drug: Oral Azelaprag (BGE-105)",
                        "Drug: Tirzepatide Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Oral Azelaprag (BGE-105)",
                    "description": "Capsules",
                    "armGroupLabels": [
                        "B: Azelaprag once daily plus Tirzepatide",
                        "C: Azelaprag twice daily plus Tirzepatide",
                        "D: Azelaprag Monotherapy"
                    ],
                    "otherNames": [
                        "BGE-105"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Oral Placebo for Azelaprag (BGE-105)",
                    "description": "Capsules",
                    "armGroupLabels": [
                        "A: Tirzepatide Monotherapy",
                        "B: Azelaprag once daily plus Tirzepatide"
                    ],
                    "otherNames": [
                        "Placebo"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Tirzepatide",
                    "description": "Subcutaneous Injection",
                    "armGroupLabels": [
                        "A: Tirzepatide Monotherapy",
                        "B: Azelaprag once daily plus Tirzepatide",
                        "C: Azelaprag twice daily plus Tirzepatide"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Tirzepatide Placebo",
                    "description": "Subcutaneous Injection",
                    "armGroupLabels": [
                        "D: Azelaprag Monotherapy"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Mean Percent Change in Body Weight (Azelaprag Once per Day)",
                    "description": "Mean percent change in body weight from baseline to Week 24 in the 300 mg azelaprag once per day (QD) plus tirzepatide arm compared to tirzepatide alone arm",
                    "timeFrame": "Week 24"
                },
                {
                    "measure": "Mean Percent Change in Body Weight (Azelaprag Twice per Day)",
                    "description": "Mean percent change in body weight from baseline to Week 24 in the 300 mg azelaprag twice per day (BID) plus tirzepatide arm compared to tirzepatide alone arm",
                    "timeFrame": "Week 24"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "\u22655% Body Weight Reduction",
                    "description": "Proportion of study participants at 24 weeks who achieve \u22655% body weight reduction from baseline for azelaprag plus tirzepatide compared to tirzepatide alone",
                    "timeFrame": "Week 24"
                },
                {
                    "measure": "\u226510% Body Weight Reduction",
                    "description": "Proportion of study participants at 24 weeks who achieve \u226510% body weight reduction from baseline for azelaprag plus tirzepatide compared to tirzepatide alone",
                    "timeFrame": "Week 24"
                },
                {
                    "measure": "\u226515% Body Weight Reduction",
                    "description": "Proportion of study participants at 24 weeks who achieve \u226515% body weight reduction from baseline for azelaprag plus tirzepatide compared to tirzepatide alone",
                    "timeFrame": "Week 24"
                },
                {
                    "measure": "\u226520% Body Weight Reduction",
                    "description": "Proportion of study participants at 24 weeks who achieve \u226520% body weight reduction from baseline for azelaprag plus tirzepatide compared to tirzepatide alone",
                    "timeFrame": "Week 24"
                },
                {
                    "measure": "Body Weight Change",
                    "description": "Change from baseline in body weight (kg) at 24 weeks for azelaprag plus tirzepatide compared to tirzepatide alone",
                    "timeFrame": "Week 24"
                },
                {
                    "measure": "Waist Circumference Change",
                    "description": "Change from baseline in in waist circumference (cm) at 24 weeks for azelaprag plus tirzepatide compared to tirzepatide alone",
                    "timeFrame": "Week 24"
                },
                {
                    "measure": "Serious Adverse Events",
                    "description": "The incidence of serious adverse events (SAEs)",
                    "timeFrame": "Up to Week 36"
                },
                {
                    "measure": "Treatment Emergent Adverse Events",
                    "description": "The incidence of treatment emergent adverse events",
                    "timeFrame": "Up to Week 36"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Male or female, 55 years of age or older at the time of signing the informed consent.\n2. Have a BMI between 30 and 40 kg/m2 inclusive at the time of screening.\n3. Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight.\n\nExclusion Criteria:\n\n1. Have diagnosis of type 1 diabetes (T1D) or Type 2 diabetes (T2D) mellitus.\n2. Have a self-reported change in body weight greater than 5 kg (11 lbs) within 90 days prior to screening.\n3. Have a prior or planned surgical treatment or device-based therapy for obesity.\n4. Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2).\n5. Have an uncontrolled thyroid disease.\n6. Have obesity induced by endocrinological disorders.\n7. Have biopsy-confirmed nonalcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH).\n8. Have a known history or presence of severe active acute or chronic livers disease or acute or chronic pancreatitis, or exocrine pancreatic insufficiency.\n9. Have a known history or presence of symptomatic gallbladder disease within the past 2 years.\n10. Have a medically significant cardiovascular condition.\n11. Have a history of active or untreated malignancy within the last 5 years.\n12. Have a history of significant active or unstable major depressive disorder or other severe psychiatric disorder within the last 2 years.\n13. Have any lifetime history of a suicide attempt.\n14. Have a known clinically significant gastric emptying abnormality.\n15. Have had previous or are currently on treatment with a GLP-1R agonist or tirzepatide (a dual agonist of GLP-1 and GIP receptors).\n16. Are currently using warfarin.\n17. Have used any weight loss drugs, including herbal or nutritional supplements, within 90 days of screening.\n18. Have current or history of treatment with medications that may cause significant weight gain within 90 days of screening.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "55 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Central Recruiting",
                    "role": "CONTACT",
                    "phone": "(888) 672-4624",
                    "email": "infobge105-005@bioagelabs.com"
                }
            ],
            "locations": [
                {
                    "facility": "Site 110",
                    "status": "RECRUITING",
                    "city": "Mesa",
                    "state": "Arizona",
                    "zip": "85210",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Central Study Contact",
                            "role": "CONTACT",
                            "email": "infobge105-005@bioagelabs.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.42227,
                        "lon": -111.82264
                    }
                },
                {
                    "facility": "Site 107",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90057",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Central Study Contact",
                            "role": "CONTACT",
                            "email": "infobge105-005@bioagelabs.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "Site 103",
                    "status": "RECRUITING",
                    "city": "Montclair",
                    "state": "California",
                    "zip": "91763",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Central Study Contact",
                            "role": "CONTACT",
                            "email": "infobge105-005@bioagelabs.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.07751,
                        "lon": -117.68978
                    }
                },
                {
                    "facility": "Site 105",
                    "status": "RECRUITING",
                    "city": "Spring Valley",
                    "state": "California",
                    "zip": "91978",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Central Study Contact",
                            "role": "CONTACT",
                            "email": "infobge105-005@bioagelabs.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.74477,
                        "lon": -116.99892
                    }
                },
                {
                    "facility": "Site 114",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Macon",
                    "state": "Georgia",
                    "zip": "31210",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Central Study Contact",
                            "role": "CONTACT",
                            "email": "infobge105-005@bioagelabs.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.84069,
                        "lon": -83.6324
                    }
                },
                {
                    "facility": "Site 100",
                    "status": "RECRUITING",
                    "city": "Louisville",
                    "state": "Kentucky",
                    "zip": "40213",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Central Study Contact",
                            "role": "CONTACT",
                            "email": "infobge105-005@bioagelabs.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.25424,
                        "lon": -85.75941
                    }
                },
                {
                    "facility": "Site 101",
                    "status": "RECRUITING",
                    "city": "Marrero",
                    "state": "Louisiana",
                    "zip": "70072",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Central Study Contact",
                            "role": "CONTACT",
                            "email": "infobge105-005@bioagelabs.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.89937,
                        "lon": -90.10035
                    }
                },
                {
                    "facility": "Site 112",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02114",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Central Study Contact",
                            "role": "CONTACT",
                            "email": "infobge105-005@bioagelabs.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Site 111",
                    "status": "RECRUITING",
                    "city": "Troy",
                    "state": "Michigan",
                    "zip": "48098",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Central Study Contact",
                            "role": "CONTACT",
                            "email": "infobge105-005@bioagelabs.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.60559,
                        "lon": -83.14993
                    }
                },
                {
                    "facility": "Site 113",
                    "status": "RECRUITING",
                    "city": "Saint Peters",
                    "state": "Missouri",
                    "zip": "63303",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Central Study Contact",
                            "role": "CONTACT",
                            "email": "infobge105-005@bioagelabs.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.80033,
                        "lon": -90.62651
                    }
                },
                {
                    "facility": "Site 106",
                    "status": "RECRUITING",
                    "city": "Butte",
                    "state": "Montana",
                    "zip": "59701",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Central Study Contact",
                            "role": "CONTACT",
                            "email": "infobge105-005@bioagelabs.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 46.00382,
                        "lon": -112.53474
                    }
                },
                {
                    "facility": "Site 109",
                    "status": "RECRUITING",
                    "city": "Fargo",
                    "state": "North Dakota",
                    "zip": "58104",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Central Study Contact",
                            "role": "CONTACT",
                            "email": "infobge105-005@bioagelabs.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 46.87719,
                        "lon": -96.7898
                    }
                },
                {
                    "facility": "Site 108",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Beachwood",
                    "state": "Ohio",
                    "zip": "44122",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Central Study Contact",
                            "role": "CONTACT",
                            "email": "infobge105-005@bioagelabs.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.4645,
                        "lon": -81.50873
                    }
                },
                {
                    "facility": "Site 102",
                    "status": "RECRUITING",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75230",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Central Study Contact",
                            "role": "CONTACT",
                            "email": "infobge105-005@bioagelabs.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                },
                {
                    "facility": "Site 104",
                    "status": "RECRUITING",
                    "city": "Saint George",
                    "state": "Utah",
                    "zip": "84790",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Central Study Contact",
                            "role": "CONTACT",
                            "email": "infobge105-005@bioagelabs.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.10415,
                        "lon": -113.58412
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Zepbound\u2122 USPI",
                    "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s003lbl.pdf"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009765",
                    "term": "Obesity"
                }
            ],
            "ancestors": [
                {
                    "id": "D000050177",
                    "term": "Overweight"
                },
                {
                    "id": "D000044343",
                    "term": "Overnutrition"
                },
                {
                    "id": "D000009748",
                    "term": "Nutrition Disorders"
                },
                {
                    "id": "D000001835",
                    "term": "Body Weight"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5114",
                    "name": "Body Weight",
                    "relevance": "LOW"
                },
                {
                    "id": "M12701",
                    "name": "Obesity",
                    "asFound": "Obesity",
                    "relevance": "HIGH"
                },
                {
                    "id": "M26186",
                    "name": "Overweight",
                    "relevance": "LOW"
                },
                {
                    "id": "M25307",
                    "name": "Overnutrition",
                    "relevance": "LOW"
                },
                {
                    "id": "M12684",
                    "name": "Nutrition Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000629749",
                    "term": "Tirzepatide"
                }
            ],
            "ancestors": [
                {
                    "id": "D000054795",
                    "term": "Incretins"
                },
                {
                    "id": "D000006728",
                    "term": "Hormones"
                },
                {
                    "id": "D000006730",
                    "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M26997",
                    "name": "Glucagon-Like Peptide 1",
                    "relevance": "LOW"
                },
                {
                    "id": "M204206",
                    "name": "Tirzepatide",
                    "asFound": "DISKUS",
                    "relevance": "HIGH"
                },
                {
                    "id": "M27905",
                    "name": "Incretins",
                    "relevance": "LOW"
                },
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M9788",
                    "name": "Hormone Antagonists",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}